Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock ...

Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Netflix, whose fourth-quarter earnings published overnight blew past analysts’ forecasts, gained 9.7 per cent, pulling other technology stocks higher. Oracle jumped 6.8 per cent and Microsoft added ...

The Nifty fell significantly, closing 320 points lower at 23,025, weighed down by continuous foreign institutional investor ...